Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZoetisXSWX:ZTS +2.39%63 EV-to-EBITDA is 9.95 as of Jul. 17, 2026, which is 57% below its 10-year median of 23.24. GuruFocus rates XSWX:ZTS with a GF Score™ of 63/100 and a GF Value™ of CHF156.38 (Significantly Undervalued). Among 741 Drug Manufacturers companies, Zoetis ranks better than 64.37% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zoetis's enterprise value is CHF31,998 Mil.
Zoetis's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was CHF3,215 Mil. Therefore, Zoetis's EV-to-EBITDA for today is 9.95.
The historical rank and industry rank for Zoetis's EV-to-EBITDA or its related term are showing as below:
XSWX:ZTS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.6 Med: 23.24 Max: 38.76
Current: 9.82
During the past 13 years, the highest EV-to-EBITDA of Zoetis was 38.76. The lowest was 9.60. And the median was 23.24.
XSWX:ZTS's EV-to-EBITDA is ranked better than 64.37% of 741
companies
in the Drug Manufacturers industry
Industry Median: 13.03
vs XSWX:ZTS: 9.82
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-17), Zoetis's stock price is CHF61.79.
Zoetis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF4.817. Therefore, Zoetis's PE Ratio (TTM) for today is 12.83.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Zoetis (XSWX:ZTS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zoetis's share price for today is CHF61.79.
Zoetis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF4.817.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Zoetis's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:ZTS vs UTHR, VTRS, NBIX: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zoetis's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zoetis's EV-to-EBITDA falls into.
Zoetis's current Enterprise Value is CHF31,998 Mil.
Zoetis's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF3,215 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis (XSWX:ZTS) has a EV-to-EBITDA of 9.95 as of Jul. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zoetis. This is 57% below median its historical median of 23.24. Over the past decade, Zoetis' EV-to-EBITDA has ranged from 9.60 to 38.76. According to the industry distribution chart, Zoetis ranks #264 out of 741 companies in the Drug Manufacturers industry, placing it in the top 35.6%.
Is Zoetis' EV-to-EBITDA too high?
Zoetis' current EV-to-EBITDA of 9.95 is 57% below median its 10-year median of 23.24. Over the past 10 years, this metric has ranged from a low of 9.60 to a high of 38.76. The Drug Manufacturers industry median EV-to-EBITDA is 13.03. Zoetis' value of 9.95 is 23.6% below this industry median. Based on the distribution chart, Zoetis ranks #264 out of 741 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zoetis has a GF Score™ of 63/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' EV-to-EBITDA compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #264 out of 741 companies for EV-to-EBITDA. This puts Zoetis in the upper half of its industry. The industry median EV-to-EBITDA is 13.03. Zoetis' value of 9.95 is 23.6% below this benchmark. Historically, Zoetis' own EV-to-EBITDA has ranged from 9.60 to 38.76 over the past decade. While the company's 10-year median is 23.24 vs. the industry median of 13.03, Zoetis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.03, based on 741 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zoetis's current EV-to-EBITDA of 9.95 is 23.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Zoetis. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zoetis's current EV-to-EBITDA is 9.95, which is 57% below median its own 10-year median of 23.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (XSWX:ZTS) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF156.38, compared to a current price of CHF61.79 — trading 60.5% below its estimated fair value. The current EV-to-EBITDA is 9.95, which is 57% below median its 10-year median of 23.24 and 23.6% below the Drug Manufacturers industry median of 13.03. Zoetis' overall GF Score™ is 63/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Zoetis (XSWX:ZTS), the current EV-to-EBITDA is 9.95 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zoetis (XSWX:ZTS) Overvalued in 2026?
Based on GuruFocus' analysis, Zoetis stock appears to be undervalued.
The current stock price of CHF61.79 is trading 60.5% below its estimated GF Value™ of CHF156.38.
GuruFocus considers Zoetis to be Significantly Undervalued.
Key valuation signals for XSWX:ZTS:
EV-to-EBITDA: 9.95 (57% below median its 10-year median of 23.24)
GF Value™: CHF156.38 vs. price of CHF61.79 (60.5% below fair value)
Industry Position: 23.6% below the Drug Manufacturers median (#264 of 741)
No single metric tells the full story. See the XSWX:ZTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
63GF Score
Get the complete analysis for XSWX:ZTS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZTS has been successfully added to your 
